Watertime, Author at PsyNews.com

Home Authors Posts by Watertime

500 POSTS 0 COMMENTS

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude...

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh...

February 2026 Psychedelic Bill Round-up

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

1...8910...50 Page 9 of 50

EDITOR PICKS

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Watertime

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude...

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh...

February 2026 Psychedelic Bill Round-up

The State of the Psychedelic Industry & Open Questions (Video)

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley...

EDITOR PICKS

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY